Does the media favor PRME or SPRB?

In the previous week, Prime Medicine had 6 more articles in the media than Spruce Biosciences. MarketBeat recorded 16 mentions for Prime Medicine and 10 mentions for Spruce Biosciences. Prime Medicine's average media sentiment score of 0.28 beat Spruce Biosciences' score of 0.05 indicating that Prime Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spruce Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SPRB or ARTV more profitable?

Artiva Biotherapeutics' return on equity of -53.86% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Spruce Biosciences N/A -123.53% -90.35% Artiva Biotherapeutics N/A -53.86% -48.16%

Does the media favor SPRB or ARTV?

In the previous week, Spruce Biosciences and Spruce Biosciences both had 10 articles in the media. Artiva Biotherapeutics' average media sentiment score of 0.64 beat Spruce Biosciences' score of 0.05 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Artiva Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SPRB or RGNX?

In the previous week, REGENXBIO had 5 more articles in the media than Spruce Biosciences. MarketBeat recorded 15 mentions for REGENXBIO and 10 mentions for Spruce Biosciences. REGENXBIO's average media sentiment score of 0.83 beat Spruce Biosciences' score of 0.05 indicating that REGENXBIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral REGENXBIO 3 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SPRB or ZURA more profitable?

Zura Bio's return on equity of -56.13% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Spruce Biosciences N/A -123.53% -90.35% Zura Bio N/A -56.13% -50.15%

Does the media favor SPRB or ZURA?

In the previous week, Spruce Biosciences had 5 more articles in the media than Zura Bio. MarketBeat recorded 10 mentions for Spruce Biosciences and 5 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.44 beat Spruce Biosciences' score of 0.05 indicating that Zura Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Zura Bio 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SPRB or EVMN more profitable?

Evommune's return on equity of -62.63% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Spruce Biosciences N/A -123.53% -90.35% Evommune N/A -62.63% -40.55%

Does the media refer more to SPRB or EVMN?

In the previous week, Evommune had 2 more articles in the media than Spruce Biosciences. MarketBeat recorded 12 mentions for Evommune and 10 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.05 beat Evommune's score of -0.53 indicating that Spruce Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Evommune 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Spruce Biosciences (SPRB) Competitors

$52.92 +0.28 (+0.53%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$52.00 -0.92 (-1.74%)

As of 04:00 AM Eastern

Compare

SPRB vs. PRME, ARTV, RGNX, ZURA, and EVMN

Should you buy Spruce Biosciences stock or one of its competitors? Spruce Biosciences's main competitors and comparable companies include Prime Medicine (PRME), Artiva Biotherapeutics (ARTV), REGENXBIO (RGNX), Zura Bio (ZURA), and Evommune (EVMN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Spruce Biosciences compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Spruce Biosciences has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	124.18	-$201.14M	-$1.06	N/A
Spruce Biosciences	$4.91M	30.93	-$38.97M	-$39.78	N/A

In the previous week, Prime Medicine had 6 more articles in the media than Spruce Biosciences. MarketBeat recorded 16 mentions for Prime Medicine and 10 mentions for Spruce Biosciences. Prime Medicine's average media sentiment score of 0.28 beat Spruce Biosciences' score of 0.05 indicating that Prime Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spruce Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spruce Biosciences has a net margin of 0.00% compared to Prime Medicine's net margin of -4,613.11%. Spruce Biosciences' return on equity of -123.53% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,613.11%	-188.27%	-59.11%
Spruce Biosciences	N/A	-123.53%	-90.35%

Prime Medicine has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.23, meaning that its stock price is 223% more volatile than the broader market.

Prime Medicine presently has a consensus target price of $7.53, indicating a potential upside of 137.58%. Spruce Biosciences has a consensus target price of $159.50, indicating a potential upside of 201.40%. Given Spruce Biosciences' higher possible upside, analysts clearly believe Spruce Biosciences is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 16.0% of Prime Medicine shares are held by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Spruce Biosciences beats Prime Medicine on 9 of the 17 factors compared between the two stocks.

How does Spruce Biosciences compare to Artiva Biotherapeutics?

Spruce Biosciences (NASDAQ:SPRB) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Spruce Biosciences currently has a consensus price target of $159.50, suggesting a potential upside of 201.40%. Artiva Biotherapeutics has a consensus price target of $39.00, suggesting a potential upside of 232.20%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Artiva Biotherapeutics is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Spruce Biosciences has higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	30.93	-$38.97M	-$39.78	N/A
Artiva Biotherapeutics	N/A	N/A	-$83.86M	-$3.30	N/A

In the previous week, Spruce Biosciences and Spruce Biosciences both had 10 articles in the media. Artiva Biotherapeutics' average media sentiment score of 0.64 beat Spruce Biosciences' score of 0.05 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Artiva Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.7% of Spruce Biosciences shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by company insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Artiva Biotherapeutics' return on equity of -53.86% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-123.53%	-90.35%
Artiva Biotherapeutics	N/A	-53.86%	-48.16%

Spruce Biosciences has a beta of 3.23, meaning that its share price is 223% more volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market.

Summary

Spruce Biosciences and Artiva Biotherapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Spruce Biosciences compare to REGENXBIO?

Spruce Biosciences (NASDAQ:SPRB) and REGENXBIO (NASDAQ:RGNX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Spruce Biosciences has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Spruce Biosciences' return on equity of -123.53% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-123.53%	-90.35%
REGENXBIO	-112.58%	-220.07%	-46.04%

Spruce Biosciences has higher earnings, but lower revenue than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	30.93	-$38.97M	-$39.78	N/A
REGENXBIO	$170.44M	4.39	-$193.88M	-$3.79	N/A

Spruce Biosciences has a beta of 3.23, indicating that its stock price is 223% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Spruce Biosciences currently has a consensus price target of $159.50, indicating a potential upside of 201.40%. REGENXBIO has a consensus price target of $23.73, indicating a potential upside of 109.42%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Spruce Biosciences is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by company insiders. Comparatively, 14.2% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, REGENXBIO had 5 more articles in the media than Spruce Biosciences. MarketBeat recorded 15 mentions for REGENXBIO and 10 mentions for Spruce Biosciences. REGENXBIO's average media sentiment score of 0.83 beat Spruce Biosciences' score of 0.05 indicating that REGENXBIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
REGENXBIO	3 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Spruce Biosciences beats REGENXBIO on 10 of the 16 factors compared between the two stocks.

How does Spruce Biosciences compare to Zura Bio?

Spruce Biosciences (NASDAQ:SPRB) and Zura Bio (NASDAQ:ZURA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Zura Bio's return on equity of -56.13% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-123.53%	-90.35%
Zura Bio	N/A	-56.13%	-50.15%

Spruce Biosciences has a beta of 3.23, suggesting that its share price is 223% more volatile than the broader market. Comparatively, Zura Bio has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market.

Spruce Biosciences presently has a consensus target price of $159.50, indicating a potential upside of 201.40%. Zura Bio has a consensus target price of $14.00, indicating a potential upside of 146.48%. Given Spruce Biosciences' higher probable upside, research analysts plainly believe Spruce Biosciences is more favorable than Zura Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by insiders. Comparatively, 12.4% of Zura Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Spruce Biosciences has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	30.93	-$38.97M	-$39.78	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A

In the previous week, Spruce Biosciences had 5 more articles in the media than Zura Bio. MarketBeat recorded 10 mentions for Spruce Biosciences and 5 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.44 beat Spruce Biosciences' score of 0.05 indicating that Zura Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zura Bio	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Spruce Biosciences beats Zura Bio on 8 of the 14 factors compared between the two stocks.

How does Spruce Biosciences compare to Evommune?

Spruce Biosciences (NASDAQ:SPRB) and Evommune (NYSE:EVMN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Spruce Biosciences has higher earnings, but lower revenue than Evommune. Spruce Biosciences is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	30.93	-$38.97M	-$39.78	N/A
Evommune	$13M	39.86	-$68.87M	-$11.03	N/A

Spruce Biosciences currently has a consensus price target of $159.50, indicating a potential upside of 201.40%. Evommune has a consensus price target of $43.25, indicating a potential upside of 202.87%. Given Evommune's stronger consensus rating and higher possible upside, analysts clearly believe Evommune is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Evommune's return on equity of -62.63% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-123.53%	-90.35%
Evommune	N/A	-62.63%	-40.55%

91.7% of Spruce Biosciences shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by company insiders. Comparatively, 31.1% of Evommune shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Evommune had 2 more articles in the media than Spruce Biosciences. MarketBeat recorded 12 mentions for Evommune and 10 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.05 beat Evommune's score of -0.53 indicating that Spruce Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evommune	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Evommune beats Spruce Biosciences on 11 of the 15 factors compared between the two stocks.

Get Spruce Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRB vs. The Competition

Export

Metric	Spruce Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$151.29M	$3.73B	$7.03B	$13.06B
Dividend Yield	N/A	3.69%	2.56%	10.63%
P/E Ratio	-1.33	11.49	270.81	25.39
Price / Sales	30.93	1,162.45	560.83	71.27
Price / Cash	N/A	45.11	28.87	38.47
Price / Book	1.33	17.41	11.16	6.51
Net Income	-$38.97M	-$13.19M	$3.45B	$347.22M
7 Day Performance	14.03%	0.91%	0.62%	1.27%
1 Month Performance	21.54%	2.63%	2.09%	2.72%
1 Year Performance	487.35%	54.05%	61.61%	21.85%

Spruce Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRB Spruce Biosciences	2.7658 of 5 stars	$52.92 +0.5%	$159.50 +201.4%	+487.3%	$151.29M	$4.91M	N/A	20	Earnings Report Analyst Downgrade Gap Down
PRME Prime Medicine	2.5081 of 5 stars	$3.09 -2.7%	$7.53 +144.1%	N/A	$558.65M	$4.63M	N/A	N/A
ARTV Artiva Biotherapeutics	2.8031 of 5 stars	$11.40 +0.9%	$39.00 +242.1%	+326.9%	$557.35M	$250K	N/A	81
RGNX REGENXBIO	4.0116 of 5 stars	$10.65 -0.1%	$23.73 +122.8%	+28.5%	$549.83M	$170.44M	N/A	370
ZURA Zura Bio	2.6363 of 5 stars	$5.64 +0.1%	$14.00 +148.4%	+242.2%	$534.65M	N/A	N/A	3	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRB) was last updated on 8/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spruce Biosciences (SPRB) Competitors

SPRB vs. PRME, ARTV, RGNX, ZURA, and EVMN

How does Spruce Biosciences compare to Prime Medicine?

Summary

How does Spruce Biosciences compare to Artiva Biotherapeutics?

Summary

How does Spruce Biosciences compare to REGENXBIO?

Summary

How does Spruce Biosciences compare to Zura Bio?

Summary

How does Spruce Biosciences compare to Evommune?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB vs. The Competition

Spruce Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spruce Biosciences (SPRB) Competitors

SPRB vs. PRME, ARTV, RGNX, ZURA, and EVMN

How does Spruce Biosciences compare to Prime Medicine?

Which has higher earnings & valuation, PRME or SPRB?

Does the media favor PRME or SPRB?

Is PRME or SPRB more profitable?

Which has more volatility and risk, PRME or SPRB?

Do analysts recommend PRME or SPRB?

Do insiders & institutionals have more ownership in PRME or SPRB?

Summary

How does Spruce Biosciences compare to Artiva Biotherapeutics?

Do analysts recommend SPRB or ARTV?

Which has preferable earnings & valuation, SPRB or ARTV?

Does the media favor SPRB or ARTV?

Do institutionals & insiders hold more shares of SPRB or ARTV?

Is SPRB or ARTV more profitable?

Which has more volatility & risk, SPRB or ARTV?

Summary

How does Spruce Biosciences compare to REGENXBIO?

Is SPRB or RGNX more profitable?

Which has better earnings and valuation, SPRB or RGNX?

Which has more volatility and risk, SPRB or RGNX?

Do analysts rate SPRB or RGNX?

Do institutionals & insiders have more ownership in SPRB or RGNX?

Does the media refer more to SPRB or RGNX?

Summary

How does Spruce Biosciences compare to Zura Bio?

Is SPRB or ZURA more profitable?

Which has more risk and volatility, SPRB or ZURA?

Do analysts prefer SPRB or ZURA?

Do institutionals and insiders believe in SPRB or ZURA?

Which has better valuation & earnings, SPRB or ZURA?

Does the media favor SPRB or ZURA?

Summary

How does Spruce Biosciences compare to Evommune?

Which has higher earnings and valuation, SPRB or EVMN?

Do analysts prefer SPRB or EVMN?

Is SPRB or EVMN more profitable?

Do institutionals & insiders believe in SPRB or EVMN?

Does the media refer more to SPRB or EVMN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB vs. The Competition

Spruce Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools